A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
← catalyst calendarNCT05456867 · readout in 102 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
250estimated
Sites
22
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-31 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NSCLC, Non-small-cell Lung Carcinoma
Primary outcomes
what the primary-completion date above is the date OFSafety of durvalumab in patients with unresectable locally advanced NSCLC without progression after CRT in routine practice of the Russian Federation.
measured Up to 54 month
Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation.
measured Up to 54 month
Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation separately for fix dose (1500mg every 4 weeks) and 10mg/kg every 2 weeks dosage.
measured Up to 54 month
Number of irAEs
measured Up to 54 month
Number of SAEs
measured Up to 54 month
Number of grade 3-4 AEs
measured Up to 54 month
Number of post discontinuation irAEs
measured Up to 54 month
Number of AESIs
measured Up to 54 month
Number of AEs which lead to discontinuation
measured Up to 54 month
Time to pneumonitis [median, months]
measured Up to 54 month
Distribution of pneumonitis grades
measured Up to 54 month
Nature of pneumonitis by physician diagnosis [radiation or immune-related]
measured Up to 54 month
Duration of pneumonitis [median, months]
measured Up to 54 month
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed